AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia

RecruitingNAAges 18 Years - 65 YearsAllBeijing Anzhen Hospital
💬

In plain words

What the trial is, and whether it could suit you

This study adopts a strategy combining basic research with clinical investigation to systematically explore the therapeutic value of cardioneuroablation in the treatment of vagally-mediated bradycardia. The study design fully considers the complexity of the scientific question and the feasibility of clinical translation. Through rigorous experimental design and standardized operational procedures, the reliability and reproducibility of the study results are ensured.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age range: 18 - 65 years old 2. Have symptoms related to bradycardia (syncope, dizziness, blackout, palpitations, fatigue, listlessness, inability to concentrate and decreased activity endurance, etc.) 3. Meet one of the following conditions: ①Dynamic electrocardiogram shows an average heart rate of less than 50 beats per minute or there is a heart arrest lasting more than 3 seconds during the day; ②Transient second or third degree atrioventricular conduction block without hemodynamic disorders during the day 4. The atropine test showed that the sinus heart rate increased by ≥ 25%, or the heart rate was ≥ 90 beats per minute, or the atrioventricular conduction block was significantly improved to be no more than first-degree atrioventricular conduction block. Exclusion Criteria: 1. A history of severe trauma caused by bradycardia 2. Regular use of antiarrhythmic drugs within the past 3 months 3. Prior implantation of a cardiac pacemaker 4. Existing implantation of, or indication for implantation of, electronic devices with pacing function, such as cardiac contractility modulators (CCMs), implantable cardioverter-defibrillators (ICDs), or cardiac resynchronization therapy (CRT) devices 5. Bradycardia or atrioventricular block caused by medications or other reversible factors (e.g., hyperkalemia, hypothyroidism) 6. Bradycardia or atrioventricular block associated with obstructive sleep apnea syndrome (OSAS) 7. Coronary revascularization within the past 3 months, or unstable coronary heart disease despite standardized medical treatment or revascularization 8. Stroke or transient ischemic attack (TIA) within the past 3 months 9. A history of open-heart surgery 10. Severe congenital heart disease 11. Complicated with severe ventricular arrhythmia 12. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) ≤ 35% 13. Severe cardiomyopathy, such as hypertrophic obstructive cardiomyopathy (HOCM), dilated cardiomyopathy (DCM), or cardiac amyloidosis 14. Severe aortic or mitral valve stenosis 15. Pregnancy or lactation period 16. Expected survival time of less than 1 year 17. Refusal to sign the informed consent form 18. Other conditions deemed ineligible by the researchers
💊

What it tests

  • Cardioneuroablation
  • Sham Control
📍

Where

1 site
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy